CurePSP’s Post

June is Alzheimer’s & Brain Awareness Month. Alzheimer's disease and related dementias (AD/ADRD) pose a significant public health challenge, with devastating effects on individuals, families and communities. In 2020, as many as 5.8 million individuals aged 65 or older in the US were living with AD/ADRD. By 2050, this number is projected to rise to 13.8 million. A comprehensive study is currently underway to clarify the relationship between Alzheimer’s disease and related dementias (AD/ADRD) and four toxic elements: lead, mercury, arsenic, and cadmium. These elements, often encountered by humans and animals worldwide without their knowledge, may hold crucial insights into cognitive decline.  The study, led by Aaron Specht, Assistant Professor in the Purdue University School of Health Sciences, aims to uncover the intricate connections between exposure to these toxic substances and the progression of cognitive impairment over time. This new study is one of the largest, most representative, and most racially diverse studies investigating the impact of toxic metal exposure on AD/ADRD in humans to date.  Read more in the press release from Malvern Panalytical: https://lnkd.in/eJbcdde2 #AlzheimersAwareness #BrainAwarenessMonth #EnvironmentalHealth

Can Alzheimer’s Disease be remediated? Alzheimer's Disease isn't just a medical challenge—it's a personal and global one. Watching a loved one slowly lose their memories, identity, and independence is something no family should have to endure. As our population ages, the urgency to find effective treatments and ultimately a cure becomes even more critical. We call this condition CDA – Cognitive Decline, dementia and Alzheimer’s Diease. The reason is that at pre-symptomatic stages, the expressions of those conditions are similar. CDA drains medical and personal budgets, leaving many people without life savings. Investing in CDA research isn't just about extending life; it's about enhancing quality of life. Early detection, prevention, and remediation of this disease can help millions worldwide. Advances in technology and neuroscience are offering hope, but we need continued support and collaboration across industries to accelerate these breakthroughs. In Ascento-CDA we believe in Healthy Aging, in which conditions are treated at early stages, leading to better prospects of remediation. To remediation of CDA, we are developing a Clinical Decision Support Solution to assists clinicians diagnosing and treating co-morbities leading to Cognitive Decline.  So in the near future, CDA will no longer a devastating diagnosis but a manageable condition and for many people - a thing of the past! #AlzheimersAwareness #alzheimersday2024 #Neuroscience #CDA #healthyaging

We are entering an era in medicine when new diagnostics can help change the management of #neurodegenerative diseases from “sick care” to #proactive preventative care. In an engaging and open piece about his quest to assess his own risk for dementia, Dr. Sanjay Gupta describes the potential of new, multimodal diagnostic approaches in assessing brain health and providing an action plan to optimizing it through personalized lifestyle changes and therapeutic interventions. While Dr. Gupta’s concerns are shared by most people over 50, his access to many of the types of tests used in his diagnostic journey is not. New technologies are needed to both expand access to personalized assessments of #brain health and provide ways of measuring key #biomarkers of neurodegenerative disease that are not currently measurable.   Amydis, Inc. is the leader in leveraging the #eye as a window to the brain with first-in-class ocular tracers that enable the detection of disease-related biomarkers in the retina. We are in human clinical trials exploring the eye to detect Alzheimer’s disease, Parkinson’s disease, ALS, and other diseases. We envision a future where people can turn to the Amydis #eyetest in their quest to assess their brain health and form an action plan for a healthier future. #Alzheimers #Parkinsons #ALS #patientsfirst CNN https://lnkd.in/ghh9jGSU

“A growing body of evidence suggests that, at least in a subset of individuals, Parkinson’s disease originates in the gut before affecting the central nervous system… The findings suggest that heightened monitoring for Parkinson’s symptoms in individuals with upper GI damage may be necessary. This study supports the “gut-first” hypothesis, proposing that Parkinson’s may originate in the gut before affecting the brain. 🔑 Key Facts 🔑 ‼️ Upper GI damage increases Parkinson’s disease risk by 76%. ‼️ Conditions like GERD, ulcers, and NSAID use are linked to this higher risk. ‼️ Parkinson’s may originate in the gut before it impacts the central nervous system.” #wholebodyliving #mindbodyconnection #holisticliving #parkinsonsresearch #gutbrainconnection

Ever notice how a wound turns red and warm as it heals? This is inflammation, the body’s natural response to injury or illness – and it happens in the brain, too. Neuroinflammation can be beneficial to brain health. However, high levels can lead to cell death, a known trigger for the progression of Alzheimer’s and other neurodegenerative diseases. We are just starting to understand how neuroinflammation factors into Alzheimer’s, so more research is needed to uncover the processes that link them. Read what scientists know so far and exciting research on the horizon in our new blog: https://lnkd.in/gA83pdY2

Did you enjoy your brief respite from COVID-19? Well, it seems the virus hasn't quite finished with us yet. As we navigate this ongoing situation, it's crucial to shine a light on an overlooked aspect: brain inflammation linked to COVID-19. Studies suggest a connection between the virus and significant neurological impacts, including conditions akin to Alzheimer's and Parkinson's. It's high time we address these silent but profound effects. You are welcome to read my latest post about the unspoken pandemic that is hitting new heights https://lnkd.in/e2Prik_f

Alzheimer's Reframed Sadly, every 66 seconds someone is diagnosed with Alzheimer’s – the pathway of cognitive decline and ageing. However, in the words of the universally known words of St Francis of Assisi in the famous poem, The Serenity Prayer: “God, grant me the serenity to accept the things I cannot. change, courage to change the things I can, and. wisdom to know the difference”. “Where there is doubt, faith; where there is despair, hope”. But what if there was a way to prevent and even reverse cognitive decline? The Bredesen Protocol is a personalized approach to better brain and gut health that addresses the many factors that lead to Alzheimer's disease. By removing exposure triggers, optimizing health support, and rebuilding the neural network, this protocol may slow the progression of the disease. While there is no single drug that can treat Alzheimer's, the Bredesen Protocol offers hope for those looking to take a proactive approach to their cognitive health. Dr. Dale Bredesen's research has culminated in the first program to prevent and reverse some cognitive decline in many participants. An interesting finding in this field is the recent article on the link between gut inflammation, aging, and Alzheimer's disease. Additionally, Functional Medicine Certified Health Coach and Certified Re:Code 2.0 Health Coach Lindsey Byrne provides excellent insight into these topics on the podcast series "Metabolic Wellbeing without the BS" in an episode titled "The Value of NOT having Alzheimer's." Let's work to reframe our understanding of Alzheimer's disease and take a personalized, proactive approach to our cognitive health #guthealth #alzheimers #functionalmedicine #functionalnutrition #inflammation #prevention #personalisedcare https://lnkd.in/e-SUAd8G

Traditionally, Alzheimer’s disease has been linked to the accumulation of beta-amyloid in the brain, with the buildup of the protein seen as a hallmark of the disease. However, Baroness Susan Greenfield CBE, NeuRA’s expert in residence this week, has co-authored a paper, ‘Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid’ published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association®, which explores the possibility of even earlier trigger, which may lead to treatments that prevent the build-up of beta-amyloid from starting. The paper reviews evidence for this upstream mechanism, including the role of a little-known neurochemical in driving the process. To learn more, listen to Baroness Greenfield’s full interview with Dr Norman Swan for the Australian Broadcasting Corporation (ABC) Health Report here: https://ab.co/4axU7Bz #AlzheimersResearch #NeuroStarAtNeuRA

𝗝𝗼𝗶𝗻 𝗗𝗿. 𝗝𝗲𝗳𝗳 𝗚𝗲𝗹𝗯𝗹𝘂𝗺 𝗼𝗻 𝗙𝗮𝗰𝗲𝗯𝗼𝗼𝗸 𝗮𝘀 𝗵𝗲 𝘁𝗮𝗹𝗸𝘀 𝗮𝗯𝗼𝘂𝘁 𝗕𝗶𝗼𝗳𝗹𝗮𝘃𝗼𝗻𝗼𝗶𝗱𝘀 𝗮𝗻𝗱 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗼𝗻 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟭𝟴 𝗮𝘁 𝟭𝟮:𝟯𝟬 𝗘𝗗𝗧. https://lnkd.in/eWUCcth Bioflavonoids, a subgroup of flavonoids, have shown promising effects on brain health. These compounds are known for their neuroprotective properties, which include protecting neurons from injury, reducing #neuroinflammation, and enhancing cognitive functions such as #memory and learning. Research has shown that flavonoids have a range of health benefits, including antioxidant, anti-inflammatory and anti-cancer properties. They've been linked to a reduced risk of chronic diseases such as #cardiovasculardisease, as well as improvements in cognitive performance, and may play a role in preventing or delaying neurodegenerative diseases like #Alzheimersdisease by inhibiting amyloid-beta aggregation and neurofibrillary tangle formation. #firstchoiceneurology #flavonoids #bioflavonoids #drjeffreygelblum #facebook

The rising incidence of brain diseases highlights the need for increased efficiency to expand access to #MRI and improved qualitative and quantitative imaging tools to improve the accuracy, timeliness and efficiency of diagnosis, both of which are the primary benefits of using STAGE. Check out this timely article via The Guardian highlighting new research that finds that neurological conditions are now the leading cause of ill-health worldwide: https://lnkd.in/d3_3Fhe9